Baylor Research Inst — research payments reported

By program year

5 rows

Year	Kind	Amount	Payments
2025	Research	$359,573	12
2024	Research	$175,449	10
2023	Research	$114,713	8
2022	Research	$133,068	12
2021	Research	$101,494	11

Breakdown

Who paid Research payments · program years 2021–2025

AstraZeneca Pharmaceuticals LP $640,145 28 payments
Acerta Pharma LLC $183,959 19 payments
AstraZeneca UK Limited $51,684 3 payments
Alexion Pharmaceuticals, Inc. $5,841 1 payment
AstraZeneca AB $2,668 2 payments

Studies the money was for Research payments · program years 2021–2025

A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate MDI on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease THARROS $142,730 2 payments
A Randomized, Multicenter, Open-Label, 3 Arm Phase 3 Study of Obinutuzumab in Combination with Chlorambucil, ACP-196 in Combination with Obinutuzumab, and ACP-196 Monotherapy in Subjects with Previously Untreated Chronic Lymphocytic Leukemia $116,596 5 payments
The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and or require systemic corticosteroid or monoclonal antibod $111,876 3 payments
An Open-label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-tumor activity of N0112 in Human Leukocyte Antigen-C0802-Positive Adult Subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for the KRAS G12D Mutation $87,355 1 payment
A Phase III, Multicentre, Randomised, Double blind, Parallel group, Placebo controlled Study to Evaluate the Efficacy and Safety of Tozorakimab (MEDI3506) in Patients Hospitalised for Viral Lung Infection Requiring Supplemental Oxygen (TILIA) $51,872 1 payment
A Two Part Phase IIa b Multicentre, Randomised, Double-Blind, Placebo-Controlled, Parallel Group Dose-ranging Study to Assess Efficacy, Safety, and Tolerability of the Combination of Zibotentan and Dapagliflozin, and Dapagliflozin Monotherapy Versus Placebo in Participants with Cirrhosis with Features of Portal Hypertension $51,867 2 payments
A Study of Bendamustine and Rituximab Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated Mantle Cell Lymphoma $45,991 14 payments
Artemide Lung02 a phase III global study of rilvegostomig or pembrolizumab for patients with metastatic squamous non small cell lung cancer $39,098 1 payment
A Phase I/II Open-Label Multicentre 2-Part Study to Assess the Safety Tolerability Pharmacokinetics and Efficacy of AZD2811 Nanoparticle as Monotherapy or in Combination in Treatment-Na?ve or Relapsed/Refractory Acute Myeloid Leukaemia/Myelodysplastic Syndrome Patients Not Eligible for Intensive Induction Therapy $36,234 1 payment
A Phase III Randomized Double blind Multicenter Global Study of Rilvegostomig or Pembrolizumab in Combination with Platinum based Chemotherapy for the First line Treatment of Patients with Metastatic Non squamous Non small Cell Lung Cancer Whose Tumors Express PDL1 ARTEMIDE Lung03 $33,848 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.